^
    Back
    Association details:
    Biomarker:CHEK2 mutation
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:irinotecan (Topoisomerase I inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO-GI 2023
    Title:

    ATM or CHEK2 alterations: Potential biomarkers of improved outcomes with irinotecan-containing chemotherapy in advanced pancreatic ductal adenocarcinoma.

    Published date:
    01/17/2023
    Excerpt:
    Irinotecan is a topoisomerase 1 inhibitor that induces DNA strand breaks, potentially causing synthetic lethality in tumors with DNA damage repair deficits due to ATM or CHEK2 alterations. IRI-containing therapy out-performed other treatment types, including platinum-containing regimens, in pts with ATM or CHEK2-mutated advanced/metastatic PDAC.
    DOI:
    10.1200/JCO.2023.41.3_suppl.754